Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 683 participants.
Also called NCT01896232
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 683 participants
- Sponsor
- Registry
-
NCT01896232 -
2013-000192-33
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Belgium, Canada, Czechia, Denmark, Estonia, France, Germany, Greece, Hungary, Italy, Latvia, Lithuania, New Zealand, Poland, Portugal, Russia, Spain, Sweden, Switzerland, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT01896232. Randomized; double masking; primary purpose treatment. Start 2013-08-13 (actual); primary completion 2014-11-12 (actual). Results posted on 2017-02-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
- Condition
- Secondary Hyperparathyroidism
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Etelcalcetide
- Intervention (Drug)
- Cinacalcet
- Intervention (Drug)
- Oral Placebo
- Intervention (Drug)
- Intravenous Placebo
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct01896232- Content hash
41707a8a700490b4b25da6e96838a44e2f2042afba9502ce62e5c24e72e10678